Prognostic value of STC1 in solid tumors: a meta-analysis

The prognostic value of STC1 has been evaluated in solid tumors. However, the results remain controversial. Relevant studies published up to 27 February 2021 were identified by a comprehensive search of the PubMed, EMBASE and Web of Science databases. Hazard ratios (HRs) and odds ratios with 95% CIs...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biomarkers in medicine 2022-03, Vol.16 (4), p.253-263
Hauptverfasser:	Li, Rongqi, Liu, Rongqiang, Wu, Shinan, Zheng, Shiyang, Ye, Lei, Shao, Yi
Format:	Artikel
Sprache:	eng
Schlagworte:	cancer Disease-Free Survival Humans meta-analysis Neoplasms - diagnosis Neoplasms - genetics Neoplasms - metabolism Prognosis Progression-Free Survival Proportional Hazards Models STC1
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The prognostic value of STC1 has been evaluated in solid tumors. However, the results remain controversial. Relevant studies published up to 27 February 2021 were identified by a comprehensive search of the PubMed, EMBASE and Web of Science databases. Hazard ratios (HRs) and odds ratios with 95% CIs were applied to explore the association between STC1 and survival outcome and clinical characteristics. Sixteen articles involving 2942 participants were included in this meta-analysis. The pooled analysis showed that high STC1 expression was significantly associated with worse overall survival (HR: 1.91; 95% CI: 1.63–2.24) and disease-free survival/progression-free survival/relapse-free survival (HR: 2.01; 95% CI: 1.34–3.02). STC1 may be an effective prognostic marker in solid tumors.
ISSN:	1752-0363 1752-0371
DOI:	10.2217/bmm-2021-0835